

BLUE SHIELD OF CALIFORNIA FOUNDATION

California Technology Assessment Forum

June 29, 2011

Los Angeles Sheraton Gateway, Los Angeles

SUMMARY OF PANEL ACTIONS

1. Call to Order and Welcome Guests – Dan Ulyot, M.D.
2. Voted to approve the minutes from February 16, 2011 CTAF meeting.
3. Technology Assessment Criteria review – Judith Walsh, M.D.
4. Fifteen members of the California Technology Assessment Forum (CTAF) panel were in attendance. This provided a quorum. The CTAF panel took the following actions:

A. Radio Frequency Ablation for the Treatment of Dysplastic Barrett's Esophagus – Low Grade Dysplasia

The following recommendation was put before the CTAF panel for consideration:

- It is recommended that RFA for the treatment of BE does not meet CTAF Criteria 4 through 5 for the treatment of individuals with low grade dysplasia (LGD).

Following panel discussion a motion was made by the CTAF Panel Discussion Leader to approve the recommendation as presented in the assessment. The motion was seconded.

The panel voted nine in favor of the recommendation and six opposed. The motion carried.

B. Stereotactic Body Radiation Therapy for the Treatment of Early Stage Non-Small Cell Lung Cancer

The following recommendations were put before the CTAF panel for consideration:

- It is recommended that stereotactic body radiation therapy for the treatment of early stage lung cancer in medically inoperable patients with peripheral lesions meets CTAF TA criteria 2 through 5 for safety, effectiveness and improvement in outcomes.
- It is recommended that stereotactic body radiation therapy for the treatment of early stage, non-small cell lung cancer in medical inoperable patients with central lesions and medically operable patients does not meet CTAF TA criteria 2 through 5 for safety, effectiveness and improvement in outcomes.

Following panel discussion a motion was made by the CTAF Panel Discussion Leader to approve the recommendation as presented in the assessment. The motion was seconded.

The CTAF panel voted unanimously in favor of the recommendation. The motion carried.

C. Aqueous Shunts for the Treatment of Glaucoma

The following recommendation was put before the CTAF panel for consideration:

- It is recommended that the use of aqueous shunts for the treatment of glaucoma not adequately controlled by medication and/or laser therapy meets CTAF TA Criterion 1 through 5 for safety, effectiveness and improvement in health outcomes.

Following panel discussion a motion was made by the CTAF Panel Discussion Leader to approve the recommendation as presented in the assessment. The motion was seconded.

The panel voted unanimously in favor of the recommendation. The motion carried.

D. Cryoballoon Ablation for Atrial Fibrillation

The following recommendation was put before the CTAF panel for consideration:

- It is recommended that cryoballoon ablation as a treatment for atrial fibrillation does not meet CTAF TA criteria 4 or 5 for improvement in health outcomes.

Following panel discussion a motion was made by the CTAF Panel Discussion Leader to approve the recommendation as presented in the assessment. The motion was seconded.

The panel voted 14 in favor of the recommendation with one abstention. The motion carried.

E. Home Telemonitoring for the Management of Heart Failure

The following recommendation was put before the CTAF panel for consideration:

- It is recommended that use of home telemonitoring for patients with heart failure does not meet CTAF TA Criterion 3 through 5 for safety, effectiveness and improvement in health outcomes.

Following panel discussion a motion was made by the CTAF Panel Discussion Leader to approve the recommendation as presented in the assessment. The motion was seconded.

The panel voted unanimously in favor of the recommendation. The motion carried.

The meeting was adjourned at 4:15P.M. The next meeting of the California Technology Assessment Forum will be held on October 19, 2011 at the Mission Bay Conference Center in San Francisco, California.